![Alex Lenz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Alex Lenz has a current job as Head of Operations and Lead Finance at Fluidform LLC since 2019.
Posizioni attive di Alex Lenz
Società | Posizione | Inizio |
---|---|---|
Fluidform LLC
![]() Fluidform LLC Industrial MachineryProducer Manufacturing FluidForm, Inc. is a company based in Waltham, MA. FluidForm is the world leader in functional human tissue for research, repair, and replacement. FluidForm, Inc. has developed a patented fresh 3D printing technology that is considered the most advanced biofabrication platform in the world. The company's robust pipeline includes the development of bioprosthetic implantable medical devices and a new generation of tissue models to test drug efficacy and cardiotoxicity. The company's ultimate focus is on tissue and organ replacement. FluidForm is transforming regenerative medicine by 3D bioprinting human tissue for drug discovery, surgical repair, and organ transplant. The company was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO of the company since 2018. | Direttore Finanziario/CFO | 01/01/2019 |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Fluidform LLC
![]() Fluidform LLC Industrial MachineryProducer Manufacturing FluidForm, Inc. is a company based in Waltham, MA. FluidForm is the world leader in functional human tissue for research, repair, and replacement. FluidForm, Inc. has developed a patented fresh 3D printing technology that is considered the most advanced biofabrication platform in the world. The company's robust pipeline includes the development of bioprosthetic implantable medical devices and a new generation of tissue models to test drug efficacy and cardiotoxicity. The company's ultimate focus is on tissue and organ replacement. FluidForm is transforming regenerative medicine by 3D bioprinting human tissue for drug discovery, surgical repair, and organ transplant. The company was founded in 2018 by Adam Feinberg and Mike Graffeo. Mike Graffeo has been the CEO of the company since 2018. | Producer Manufacturing |
- Borsa valori
- Insiders
- Alex Lenz